Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


14.06.2021

1 AIDS
2 Am J Gastroenterol
1 BMC Gastroenterol
1 Clin Infect Dis
1 Dig Dis Sci
3 Eur J Gastroenterol Hepatol
1 Gut
6 Hepatology
9 J Hepatol
2 J Med Virol
3 J Viral Hepat
1 J Virol
1 N Engl J Med
1 PLoS Med
3 PLoS One
2 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. GUARDIGNI V, Toschi A, Badia L, Del Turco ER, et al
    Patients living with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for HCV.
    AIDS. 2021 Jun 4. pii: 00002030-900000000-96387.
    PubMed         Abstract available


    Am J Gastroenterol

  2. YU X
    Pay Attention to Distinguish Hepatitis from Novel Coronavirus Hepatitis in the Context of COVID-19 Pandemic.
    Am J Gastroenterol. 2021;116:1354-1355.
    PubMed        

  3. RINALDI L, Messina V, Di Marco V, Iovinella V, et al
    Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.
    Am J Gastroenterol. 2021;116:1248-1255.
    PubMed         Abstract available


    BMC Gastroenterol

  4. ALQAHTANI SA, Broering DC, Alghamdi SA, Bzeizi KI, et al
    Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease.
    BMC Gastroenterol. 2021;21:245.
    PubMed         Abstract available


    Clin Infect Dis

  5. VALERIO H, Alavi M, Law M, McManus H, et al
    Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study.
    Clin Infect Dis. 2021 Jun 9. pii: 6295650. doi: 10.1093.
    PubMed         Abstract available


    Dig Dis Sci

  6. CHEN J, Hubbard A, Bagley L, Shiau R, et al
    Prevalence of Latent Tuberculosis Infection Among Persons with Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis.
    Dig Dis Sci. 2021 May 30. pii: 10.1007/s10620-021-07056.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  7. SHI K, Li P, Xue D, Liu Y, et al
    Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97202.
    PubMed         Abstract available

  8. KOSEKLI MA
    Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97205.
    PubMed         Abstract available

  9. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed         Abstract available


    Gut

  10. URBAN S, Neumann-Haefelin C, Lampertico P
    Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
    Gut. 2021 Jun 8. pii: gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.
    PubMed         Abstract available


    Hepatology

  11. YANG Z, Zhang T, Kusumanchi P, Tang Q, et al
    Transcriptomic analysis reveals the miRNAs responsible for liver regeneration associated with mortality in alcoholic hepatitis.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31994.
    PubMed         Abstract available

  12. ROBERTS H, Ly KN, Yin S, Hughes E, et al
    Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31991.
    PubMed         Abstract available

  13. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    PubMed         Abstract available

  14. DE PASQUALE C, Campana S, Pollicino T, Ferlazzo G, et al
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response? Author's Reply.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32004.
    PubMed         Abstract available

  15. BEUDEKER BJB, Janssen HLA, Boonstra A
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response?
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32003.
    PubMed         Abstract available

  16. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    PubMed         Abstract available


    J Hepatol

  17. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed         Abstract available

  18. DE MARTIN E, Duclos-Vallee JC
    Reply to "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents".
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00345.
    PubMed        

  19. MARTINEZ MG, Boyd A, Combe E, Testoni B, et al
    Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00348.
    PubMed         Abstract available

  20. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
    PubMed        

  21. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed         Abstract available

  22. MATHURIN P
    Early liver transplantation for acute alcoholic hepatitis: we can't say no.
    J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
    PubMed         Abstract available

  23. LI J, Liang X, You S, Feng T, et al
    Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    J Hepatol. 2021 Jun 3. pii: S0168-8278(21)00399.
    PubMed         Abstract available

  24. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    PubMed         Abstract available

  25. ROCCO A, Sgamato C, Compare D, Nardone G, et al
    Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty.
    J Hepatol. 2021 Jun 8. pii: S0168-8278(21)00412.
    PubMed        


    J Med Virol

  26. WANG Y, Li X, Chen Q, Jiao F, et al
    The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27114.
    PubMed         Abstract available

  27. JI H, Chen S, He Q, Wang W, et al
    The different replication between nonenveloped and quasi-enveloped hepatitis E virus.
    J Med Virol. 2021 Jun 2. doi: 10.1002/jmv.27121.
    PubMed         Abstract available


    J Viral Hepat

  28. WANG S, Fang S, Liu Y
    The 5-year cumulative incidence HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    J Viral Hepat. 2021 May 29. doi: 10.1111/jvh.13553.
    PubMed         Abstract available

  29. NISHIDA Y, Imamura M, Yuji T, Morio K, et al
    Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13557.
    PubMed         Abstract available

  30. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed         Abstract available


    J Virol

  31. NAKAJIMA S, Watashi K, Kato T, Muramatsu M, et al
    Biochemical and structural properties of entecavir-resistant hepatitis B virus polymerase with L180M/M204V mutations.
    J Virol. 2021 Jun 2:JVI0240120. doi: 10.1128/JVI.02401.
    PubMed         Abstract available


    N Engl J Med

  32. PATEL TS, Teterina Mohammed E
    Porphyria Cutanea Tarda Associated with Hepatitis C.
    N Engl J Med. 2021;384:e86.
    PubMed        


    PLoS Med

  33. FADNES LT, Aas CF, Vold JH, Leiva RA, et al
    Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
    PLoS Med. 2021;18:e1003653.
    PubMed         Abstract available


    PLoS One

  34. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed         Abstract available

  35. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed         Abstract available

  36. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed         Abstract available


    Vaccine

  37. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    PubMed         Abstract available

  38. YANG T, Liu B, Yue L, Xie T, et al
    Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00653.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: